Voyager Therapeutics (NASDAQ:VYGR) Posts Earnings Results, Misses Estimates By $0.24 EPS

Voyager Therapeutics (NASDAQ:VYGR) posted its quarterly earnings data on Tuesday. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.24), Zacks reports. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%.

Voyager Therapeutics Trading Down 4.8 %

NASDAQ VYGR traded down $0.20 during mid-day trading on Tuesday, hitting $3.97. The company’s stock had a trading volume of 549,596 shares, compared to its average volume of 493,491. The company’s 50 day simple moving average is $4.98 and its 200 day simple moving average is $5.89. The firm has a market capitalization of $216.87 million, a price-to-earnings ratio of 5.59 and a beta of 0.99. Voyager Therapeutics has a twelve month low of $3.56 and a twelve month high of $10.66.

Analysts Set New Price Targets

VYGR has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Monday, March 3rd. StockNews.com downgraded Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Cantor Fitzgerald started coverage on Voyager Therapeutics in a research note on Friday, January 10th. They set an “overweight” rating and a $5.73 target price for the company. Wedbush reissued an “outperform” rating and issued a $9.00 price target (down from $11.00) on shares of Voyager Therapeutics in a research note on Tuesday, February 11th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Voyager Therapeutics has a consensus rating of “Buy” and an average price target of $15.72.

Insider Activity at Voyager Therapeutics

In related news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total transaction of $36,725.00. Following the completion of the sale, the chief operating officer now owns 112,328 shares in the company, valued at approximately $634,653.20. This represents a 5.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders have sold 10,778 shares of company stock valued at $58,548. 4.53% of the stock is owned by corporate insiders.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.